A review of IVF in PCOS patients at risk of ovarian hyperstimulation syndrome

References

• Norman RJ, Dewaily D, Legro RS, et al. Polycystic ovary_syndrome. Lancet. 2007;370:685–697.
   PubMed Web of Science ®Google Scholar
• Salim R. IVF in Polycystic ovary syndrome. In: Diagnosis and Management of Polycystic Ovary Syndrome. Farid NR & Diamantis-Kandarakis E (Eds). Boston, MA: Springer US. 2009. pp. 253–258.
   Google Scholar
• Kwik M. Preventing ovarian hyperstimulation syndrome. In: Kovacs G, Rutherford A, Gardiner D, editors. How to prepare the egg and the embryo to maximize IVF success. Cambridge, UK: Cambridge University Press; 2019. p. 9.
   Google Scholar
• Mathur RS, Tan BK. British fertility society policy and practice committee: prevention of ovarian hyperstimulation syndrome. Hum Fertil. 2014;17(4):257–268.
   Web of Science ®Google Scholar
• Cook CL, Siow Y, Taylor S, et al. Serum mullerian-inhibiting substance levels during normal menstrual cycles. Fertil Steril. 2000;73:859–861.
   PubMed Web of Science ®Google Scholar
• Lee TS, Liu CH, Huang CC, et al. Serum AMH and estradiol levels as predictors of OHSS in ART cycles. Hum Reprod. 2008;23(1):160–167.
   PubMed Web of Science ®Google Scholar
• Marci R, Senn A, Dessole S, et al. A low-dose stimulation protocol using highly purified follicle-stimulating hormone can lead to high pregnancy rates in in vitro fertilization patients with polycystic ovaries who are at risk of a high ovarian response to gonadotropins. Fertil Steril. 2001;76:1131–1135.
   Web of Science ®Google Scholar
• Van Wely M, Kwan I, Burt AL, et al. Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology. Cochrane Database Syst Rev. 2011;2. DOI:10.1002/14651858.CD005354.pub2.
   Web of Science ®Google Scholar
• Figen Turkcapar A, Sackin B, Onalan G, et al. Human menopausal gonadotropin versus recombinant FSH in polycystic ovary syndrome patients undergoing in vitro fertilization. Int J Fertil Steril. 2013;6(4):238–243.
   PubMedGoogle Scholar
• Tarlatzis BC, Fauser BC, Kolibianakis EM, et al. Brussels GnRH antagonist consensus workshop group. GnRH antagonists in ovarian stimulation for IVF. Hum Reprod Update. 2006;12:333–340.
   PubMed Web of Science ®Google Scholar
• Al-Inany HG, Youssef MA, Aboulghar M, et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2011. DOI:10.1002/14651858.CD001750.pub3.
   Web of Science ®Google Scholar
• Merviel P, Najas S, Campy H, et al. Use of GNRH antagonists in reproductive medicine. Minerva Ginecol. 2005;57:29–43.
   PubMedGoogle Scholar
• Lin K, Coutifaris C. In vitro fertilization in the polycystic ovary syndrome patient: an update. Clin Obstet Gynecol. 2007;50(1):268–276.
   PubMed Web of Science ®Google Scholar
• Tso LO, Costello MF, Albuquerque LE, et al. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2014;11:Cd006105.
   Google Scholar
• Mathur R, Joels A, Jenkins M. Ovarian hyperstimulation syndrome may be more likely if multiple pregnancy occurs following assisted conception. Acta Genet Medic Gemellol. 1995;44:233–235.
   PubMedGoogle Scholar
• D’Angelo A, Amso NN. Embryo freezing for preventing ovarian hyperstimulation syndrome: a Cochrane review. Hum Reprod. 2002;17:2787–2794.
   PubMed Web of Science ®Google Scholar
• Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update. 2002;8:559–577.
   PubMed Web of Science ®Google Scholar
• García-Velasco JA, Isaza V, Quea G, et al. Coasting for the prevention of ovarian hyperstimulation syndrome: much ado about nothing? Fertil Steril. 2006;85:547–555.
   PubMed Web of Science ®Google Scholar
• Dhont M, Van der Straeten F, De Sutter P. Prevention of severe ovarian hyperstimulation by coasting. Fertil Steril. 1998;70:847–850.
   PubMed Web of Science ®Google Scholar
• Egbase PE, Sharhan MA, Grudzinskas JG. Early unilateral follicular aspiration compared with coasting for the prevention of severe ovarian hyperstimulation syndrome: a prospective randomized study. Hum Reprod. 1999;14:2922–2923.
   PubMed Web of Science ®Google Scholar
• Busso C. Symposium: update on prediction and management of OHSS. Prevention of OHSS—dopamine agonists. Reprod Biomed Online. 2009;19:43–51.
   PubMed Web of Science ®Google Scholar
• Garcia-Velasco J. How to avoid ovarian hyperstimulation syndrome: A new indication for dopamine agonists. Reprod Biomed Online. 2009;19:71–75.
   Web of Science ®Google Scholar
• Gomez R, Gonzalez-Izquierdo M, Zimmermann RC, et al. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology. 2006;147:5400–5411.
   PubMed Web of Science ®Google Scholar
• Alvarez C, Marti-Bonmati L, Novella-Maestre E, et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab. 2007;92:2931–2937.
   PubMed Web of Science ®Google Scholar
• Humaidan P, Papanikolaou EG, Kyrou D, et al. The lutealphase after GnRH-agonist triggering of ovulation: present and future perspectives. Reprod BioMed Online. 2012;24:134–141.
   PubMed Web of Science ®Google Scholar
• Youssef MA, Van der Veen F, Al-Inany HG, et al. Gonadotropin releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles. Cochrane Database Syst Rev. 2011. DOI:10.1002/14651858.CD008046.pub3.
   Web of Science ®Google Scholar
• Babayof R, Margalioth EJ, Huleihel M, et al. Serum Inhibin A, VEGF and TNFa levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. Hum Reprod. 2006;21:1260–1265.
   PubMed Web of Science ®Google Scholar
• Engmann L, DiLuigi A, Schmidt D, et al. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian Hyperstimulation syndrome: a prospective randomised controlled study. Fertil Steril. 2008;89:84–91.
   PubMed Web of Science ®Google Scholar
• Papanikolaou EG, Verpoest W, Fatemi H, et al. A novel method of luteal supplementation with recombinant luteinizing hormone when a gonadotropin-releasing hormone agonist is used instead of human chorionic gonadotropin for ovulation triggering: a randomized prospective proof of concept study. Fertil Steril. 2011;95:1174–1177.
   PubMed Web of Science ®Google Scholar
• Humaidan P, Bredkjaer HE, Westergaard LG, et al. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Fertil Steril. 2010;93:847–854.
   PubMed Web of Science ®Google Scholar
• Seyhan A, Ata B, Polat M, et al. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG. Hum Reprod. 2013;28:2522–2528.
   PubMed Web of Science ®Google Scholar
• Humaidan P, Kol S, Papanikolaou EG. on behalf of the copenhagen GnRH agonist triggering workshop group. GnRH agonist for triggering of final oocyte maturation: time for a change of practice?. Hum Reprod Update. 2011;17:510–524.
   PubMed Web of Science ®Google Scholar
• Lee JH, Miele ME, Hicks DJ, et al. KISS-1, a novel human malignant melanoma metastasis-suppressor gene. J Natl Cancer Inst. 1996;23:1731–1737.
   Google Scholar
• Skorupskaite K, George JT, Anderson RA. The kisspeptin– gnRH pathway in human reproductive health and disease. Hum Reprod Update. 2014;20:485–500.
   PubMed Web of Science ®Google Scholar
• Abbara A, Jayasena CN, Christopoulos C, et al. Efficacy of kisspeptin-54 to trigger oocyte maturation in women at high risk of ovarian hyperstimulation syndrome (OHSS) during in vitro fertilization (IVF) therapy. J Clin Endocrinol Metab. 2015;100:3322–3331.
   PubMed Web of Science ®Google Scholar
• Wong KM, van Wely M, Mol F, et al. Fresh versus frozen embryo transfers in assisted reproduction. Cochrane Database Syst Rev. 2017;3:CD011184.
   PubMed Web of Science ®Google Scholar
• Basile N, Garcia-Velasco JA. The state of “freeze-for-all” in human ARTs. J Assist Reprod Genet. 2016;33:1543–1550.
   PubMed Web of Science ®Google Scholar
• Chen Z-J, Shi Y, Sun Y, et al. Fresh versus frozen embryos for infertility in the polycystic ovary syndrome. N Engl J Med. 2016;375:523–533.
   PubMed Web of Science ®Google Scholar
• Xu B, He Y-Q, Wang Y, et al. Frozen embryo transfer or fresh embryo transfer: clinical outcomes depend on the number of oocytes retrieved. Eur J Obstet Gynecol Reprod Biol. 2017;215:50–54.
   PubMed Web of Science ®Google Scholar